Introduction  by Qunibi, Wajeh Y.
Kidney International, Vol. 66, Supplement 90 (2004), pp. S1–S2
Introduction
Chronic kidney disease is becoming a major health
problem worldwide. The United States Renal Data
System (USRDS) estimated that there are currently
more than 400,000 patients with end-stage renal disease
(ESRD) in the United States, and more than one mil-
lion patients worldwide. Despite impressive technologic
advances in dialysis treatment, the mortality rate among
patients with ESRD remains unacceptably high, mainly
because of cardiovascular disease. While traditional risk
factors for cardiovascular disease are highly prevalent
in patients with chronic kidney disease (CKD), uremia-
related factors such as hyperphosphatemia have also
been found to contribute to this burden. In 1990, Lowrie
and Lew reported a link between high serum phospho-
rus level and increased mortality risk. Unfortunately,
their study did not receive the attention it deserved.
As a result, and almost 10 years later, another study
by Block et al showed that the average serum phospho-
rus in the United States dialysis population remained at
6.2 mg/dL, not really different from that initially reported
by Lowrie and Lew. Moreover, they reported a strong
association between high serum phosphorus level and
calcium-phosphorus product (Ca × P) product and in-
creased mortality risk. This suggests that we were content
with levels of serum phosphorus that are currently unac-
ceptable, possibly because we had not fully appreciated
the serious consequences of hyperphosphatemia in our
dialysis population.
Fortunately, the last five to 10 years have witnessed a
plethora of publications that have been vital in enhancing
our understanding of the scope of morbidity and mortal-
ity risks associated with elevated serum phosphorus. We
now understand that phosphorus is not only central to the
pathogenesis of secondary hyperparathyroidism, but also
plays a major role in the pathogenesis of extraosseous
calcification. More importantly, we now know that ele-
vated serum phosphorus can be a silent killer. Hence, we
are beginning to see a paradigm shift in our approach to
management of hyperphosphatemia.
Block and Port should be credited for being the first
to recommend more stringent control of serum phospho-
rus and Ca × P product in dialysis patients. Indeed, the
National Kidney Foundation Kidney Disease Outcome
Quality Initiative (K/DOQI) Clinical Practice Guidelines
for Bone Metabolism and Disease in Chronic Kidney Dis-
ease have largely incorporated their recommendations
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for control of serum phosphorus and Ca × P product in
order to improve patients’ quality of life and longevity.
The topics reviewed in this supplement to Kidney In-
ternational emphasize the role of hyperphosphatemia in
the increased morbidity and mortality of patients with
ESRD. Linda Szczech and Ira Lazar start the series with
a review of the burden of CKD in the United States. These
authors cite recent projections for a steady increase in the
number of patients with ESRD who will require renal re-
placement therapy over the next 25 years. They correctly
emphasize the financial impact of caring for these pa-
tients, and speculate that therapeutic interventions in the
early stages of CKD may lower the incidence of ESRD
and decrease its overall cost to health care payers.
Qunibi further expands on this topic by reviewing
the overall clinical consequences of untreated hyper-
phosphatemia. He emphasizes that, when left untreated,
hyperphosphatemia plays a major role in the pathogen-
esis of secondary hyperparathyroidism (SHPT), soft tis-
sue and cardiovascular calcification, and increased risk
of death, mainly from cardiovascular disease. He states
that chronically elevated serum phosphorus is associated
with arterial stiffness, which may be manifested by abnor-
mal hemodynamics such as elevated systolic blood pres-
sure (BP), decreased diastolic BP, and increased pulse
pressure. On the other hand, calcification of the coro-
nary arteries, the myocardium, cardiac valves, and the
conduction system may lead to various cardiac events,
such as myocardial infarction, congestive heart failure,
arrhythmia, and sudden death. As a result, we should
aim for achieving tighter control of serum phosphorus
to the goals recently recommended by the National Kid-
ney Foundation K/DOQI Clinical Practice Guidelines for
Bone Metabolism and Disease in Chronic Kidney Dis-
ease. These guidelines were designed to assist decision-
making by nephrologists in order to reduce patients’ mor-
bidity and mortality.
Alfrey provides a scholarly review of the role of phos-
phorus in the pathogenesis of extraosseous calcification.
He divides calcium phosphate deposits into two groups,
as determined by their crystallographic properties. Type I
has an x-ray diffraction pattern of hydroxyapatite, identi-
cal to that found in bone. In contrast, type II deposits have
an x-ray diffraction pattern of an amorphous compound
with thermochemical properties of whitlockite. He be-
lieves that while tumoral, conjunctival, and periarticular
calcification is clearly associated with overt hyperphos-
phatemia, the pathogenesis of visceral calcification is less
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well understood. Therefore, the pathogenic mechanisms
responsible for the development of calcium deposits in
various organs may be different.
In their review, McCullough and Soman focus on the
pathogenesis of cardiovascular calcification in patients
with CKD. Based on their extensive review of the litera-
ture, they contend that the majority of published studies
have not found a causal relationship between measures
of calcium-phosphorus balance and coronary artery cal-
cification. Moreover, they found that the most consistent
determinants of coronary artery calcification in CKD pa-
tients are the extent and duration of renal dysfunction,
as well as older age. They conclude that components
of lipid profile [primarily low high-density lipoprotein
cholesterol, elevated triglycerides, elevated low-density
lipoprotein (LDL-C), and elevated total cholesterol] are
important factors in the calcification process. Obviously,
further research into the determinants and potential
treatment for coronary artery and vascular calcification
in association with CKD is warranted.
Michael Emmett provides a detailed and scholarly re-
view of treatment options for hyperphosphatemia in pa-
tients with ESRD. He divides the history of phosphorous
binders into three overlapping eras. The first began in
the early 1970s, which was characterized by the exten-
sive use of aluminum salts. This continued until the early
1980s, when the spectrum of aluminum toxicity became
widely recognized. The second was the era of calcium
salts, which started in the early 1980s and has contin-
ued until the present time. Notably, Emmett makes a dis-
tinction between calcium acetate and calcium carbonate
by reviewing the results of short-term studies which in-
dicated that, when equal amounts of elemental calcium
was given as either calcium acetate or calcium carbonate,
the acetate salt bound more phosphate, while simultane-
ously, less calcium was absorbed. He reasons that concern
over the purported role of calcium load from calcium-
based phosphate binders in extraosseous calcification and
oversuppression of parathyroid hormone levels has stim-
ulated efforts to minimize calcium absorption by search-
ing for non-aluminum, non-calcium binders. As a result,
we have entered the third phosphorous binder era, which
is represented by the introduction of non-calcium, non-
aluminum phosphorous-binding resins and other novel
agents. However, whether these new agents are equally
effective as calcium-based phosphate binders is currently
being investigated.
Continuing on the subject of phosphate binders, Qunibi
and Nolan review the results of the CARE study, the
only prospective, randomized, double-blind study that
has compared the efficacy and safety of calcium acetate
and sevelamer HCl in hemodialysis patients. In their
opinion, the CARE study has definitively established
the superiority of calcium acetate over sevelamer HCl
for achieving the target levels of serum phosphorus and
Ca × P product recommended by K/DOQI guidelines.
Moreover, they state that calcium acetate is the more
cost-effective choice as first-line treatment for hyper-
phosphatemia in patients with ESRD on maintenance
dialysis. Of note, the doses of calcium acetate required
for control of serum phosphorus in the CARE study fall
within the 1500 to 2000 mg of elemental calcium intake
per day recommended by the K/DOQI guidelines. Finally,
Qunibi and Nolan confirm findings from previous stud-
ies which indicate that patients treated with sevelamer
HCl have lower serum bicarbonate levels than patients
treated with calcium-containing phosphate binders.
To explore this issue further, Brezina et al review in
detail the mechanisms by which hemodialysis patients
treated with sevelamer HCl consistently develop lower
serum bicarbonate levels compared with patients treated
with calcium-containing phosphate binders. They pro-
vide evidence from their preliminary study, in which rats
treated with sevelamer HCl had a significant fall in urine
pH as well as an increase in urinary ammonium and cal-
cium excretion consistent with an increase in net acid
excretion. Subsequently, they discuss the potential role
of chronic metabolic acidosis in worsening secondary hy-
perparathyroidism, net negative nitrogen and total body
protein balance, and increased risk of death in dialy-
sis patients. Therefore, the risks of sevelamer-induced
metabolic acidosis in dialysis patients clearly deserve
urgent studies.
The last paper, by Linda Szczech, offers a brief re-
view of the impact of the new calcimimetic agents on the
use of different phosphate binders. She points out that
serum calcium and phosphorus levels consistently fell in
patients receiving cinacalcet, as did their average calcium-
phosphorus product. Consequently, she speculates that
this may lead to an increase in the use of calcium-
containing phosphate binders based on their ability to
function as both phosphorus binders as well as calcium
supplements.
The contributions in this supplement reflect the cur-
rent interest of nephrologists in the role of hyperphos-
phatemia in the increased morbidity and mortality of
patients with ESRD and the options for its treatment.
In particular, given the important relationship between
hyperphosphatemia and cardiovascular calcification, sev-
eral articles review the balance of the evidence from the
literature on this relationship. It is my hope that the in-
sights presented here are of value for clinicians caring
for patients with CKD. Without the expertise and dedi-
cation of all the authors who provide these insights, this
supplement to Kidney International would not have been
possible. To each and every one of them, I extend my
sincere appreciation.
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